(Q21032526)

30 June 2019

meta-analysis

0 references

review article

1 reference

title

Vaccines for preventing malaria (SPf66) (English)

1 reference

30 June 2019

0 references

1 reference

1 reference

2

H Gelband

H

Gelband

1 reference

27 July 2022

1

P Graves

P

Graves

1 reference

27 July 2022

language of work or name

English

0 references

publication date

19 April 2006

1 reference

30 June 2019

Cochrane Database of Systematic Reviews

published in

1 reference

30 June 2019

issue

2

1 reference

30 June 2019

page(s)

CD005966

1 reference

30 June 2019

Evaluation of the SPf66 vaccine for malaria control when delivered through the EPI scheme in Tanzania

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005966

Humoral immune responses during a malaria vaccine trial in Tanzanian infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005966

Safety in infants of SPf66, a synthetic malaria vaccine, delivered alongside the EPI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005966

Immune responses to Plasmodium falciparum antigens during a malaria vaccine trial in Tanzanian children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005966

Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005966

Duration of protection and age-dependence of the effects of the SPf66 malaria vaccine in African children exposed to intense transmission of Plasmodium falciparum

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005966

A trial of the synthetic malaria vaccine SPf66 in Tanzania: rationale and design

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005966

Analysis of multiple Plasmodium falciparum infections in Tanzanian children during the phase III trial of the malaria vaccine SPf66.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005966

An efficacy trial of the malaria vaccine SPf66 in Gambian infants--second year of follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005966

Efficacy trial of malaria vaccine SPf66 in Gambian infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005966

Reduction in the mean number of Plasmodium falciparum genotypes in Gambian children immunized with the malaria vaccine SPf66.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005966

Serological responses of Gambian children to immunization with the malaria vaccine SPf66.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005966

Follow-up of Gambian children recruited to a pilot safety and immunogenicity study of the malaria vaccine SPf66.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005966

A pilot safety and immunogenicity study of the malaria vaccine SPf66 in Gambian infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005966

Field trials of an asexual blood stage malaria vaccine: studies of the synthetic peptide polymer SPf66 in Thailand and the analytic plan for a phase IIb efficacy study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005966

Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand. Shoklo SPf66 Malaria Vaccine Trial Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005966

Safety, immunogenicity and protective effect of the SPf66 malaria synthetic vaccine against Plasmodium falciparum infection in a randomized double-blind placebo-controlled field trial in an endemic area of Ecuador

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005966

Evaluation of SPf66 malaria vaccine efficacy in Brazil.

21 January 2018

2 references

https://api.crossref.org/works/10.1002%2F14651858.CD005966

21 January 2018

12 December 2020

SPf66 vaccine trial in Brazil: conceptual framework study design and analytical approach

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005966

Safety evaluation of SPf66 malaria vaccine in Brazil

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005966

Vaccination with SPf66, a chemically synthesised vaccine, against Plasmodium falciparum malaria in Colombia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005966

Evaluation of SPf66 malaria vaccine during a 22-month follow-up field trial in the Pacific coast of Colombia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005966

The first field trials of the chemically synthesized malaria vaccine SPf66: safety, immunogenicity and protectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005966

SPf66 malaria vaccine is safe and immunogenic in malaria naive adults in Thailand.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005966

A population-based clinical trial with the SPf66 synthetic Plasmodium falciparum malaria vaccine in Venezuela

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005966

A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005966

Study of the safety and immunogenicity of the synthetic malaria SPf66 vaccine in children aged 1-14 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005966

Vaccines for preventing malaria (pre-erythrocytic)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005966

Vaccines for preventing malaria (blood-stage)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005966

The global distribution and population at risk of malaria: past, present, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005966

Systematic reviews in health care: Assessing the quality of controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005966

Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005966

Progress and challenges for malaria vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005966

The global distribution of clinical episodes of Plasmodium falciparum malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005966

The SPf66 Malaria Vaccine: What is the Evidence for Efficacy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005966

Vaccines for preventing malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005966

Phase I trial of the SPf66 malaria vaccine in a malaria-experienced population in Southeast Asia.

21 January 2018

2 references

https://api.crossref.org/works/10.1002%2F14651858.CD005966

21 January 2018

12 December 2020

The world health report 2002 - reducing risks, promoting healthy life

1 reference

12 December 2020

Conquering the intolerable burden of malaria: what's new, what's needed: a summary.

1 reference

12 December 2020

Pediatric mortality in Africa: plasmodium falciparum malaria as a cause or risk?

1 reference

12 December 2020

Update on the clinical development of candidate malaria vaccines.

1 reference

12 December 2020

Randomised trial of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania.

1 reference

12 December 2020

Phase I safety and immunogenicity testing of clinical lots of the synthetic Plasmodium falciparum vaccine SPf66 produced under good manufacturing procedure conditions in the United States.

1 reference

12 December 2020

An efficacy trial of a malaria vaccine in Gambian infants and comparison with insecticide-treated bednets

1 reference

12 December 2020

Immunization with SPf66 and subsequent infection with homologous and heterologous Plasmodium falciparum parasites

1 reference

12 December 2020

10.1002/14651858.CD005966

Identifiers

DOI

1 reference

30 June 2019

PMCID

6532709

1 reference

30 June 2019

PubMed ID

16625647

1 reference

30 June 2019